# US 2013/0344056 A1 · Keratin biomaterials for treatment of ischemia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0344056 A1
- Document ID: US20130344056A1
- Status: Published application
- Kind: A1
- Application number: 14/010,902
- Filed: 2013-08-27
- Published: 2013-12-26
- Earliest claimed: 2010-03-08
- Assignees: Wake Forest University Health Sciences
- Applicants: Wake Forest University Health Sciences
- Inventors: Mark E. Van Dyke; Thomas L. Smith; Michael Callahan; Luke Burnett
- Web page: https://patentgrep.com/patent/US20130344056A1

## CPC

- A61K 38/1748: {Keratin; Cytokeratin}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/727: Heparin; Heparan
- A61K 38/015: {from keratin}
- A61K 38/166: {Streptokinase}
- A61K 38/482: {Serine endopeptidases (3.4.21)}
- A61K 38/49: Urokinase; Tissue plasminogen activator
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61L 15/44: Medicaments
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61L 2300/252: Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are keratin compositions useful for treating ischemia and/or reperfusion injury, such as that associated with myocardial infarct, ischemic stroke, brain trauma such as traumatic brain injury, hypothermia, chronic wounds, and burns.

## Claims

### Claim at position 1

-10. (canceled)

### Claim 11

A composition comprising a keratin and further comprising a thrombolytic.

### Claim 12 (depends on 11)

The composition of claim 11, wherein said keratin is selected from the group consisting of:
α-keratose, γ-keratose, keratin associated proteins (KAP), and combinations thereof.

### Claim 13 (depends on 11)

The composition of claim 11, wherein said keratin is a combination of α-keratose and keratin associated proteins (KAP).

### Claim 14 (depends on 13)

The composition of claim 13, wherein said α-keratose has an average molecular weight of at least 30 kiloDaltons.

### Claim 15 (depends on 11)

The composition of claim 11, wherein said composition comprises from 1 to 10% by weight of said keratin.

### Claim 16 (depends on 11)

The composition of claim 11, wherein said keratin is from 3 to 5 percent by weight.

### Claim 17 (depends on 11)

The composition of claim 11, wherein said composition is formulated for parenteral administration.

### Claim 18 (depends on 11)

The composition of claim 11, wherein said thrombolytic is selected from the group consisting of: streptokinase, urokinase, alteplase, reteplase, and tenecteplase.

### Claim 19

A composition comprising a keratin and further comprising an anticoagulant.

### Claim 20 (depends on 19)

The composition of claim 19, wherein said keratin is selected from the group consisting of: α-keratose, γ-keratose, keratin associated proteins (KAP), and combinations thereof.

### Claim 21 (depends on 19)

The composition of claim 19, wherein said keratin is a combination of α-keratose and keratin associated proteins (KAP).

### Claim 22 (depends on 20)

The composition of claim 20, wherein said α-keratose has an average molecular weight of at least 30 kiloDaltons.

### Claim 23 (depends on 19)

The composition of claim 19, wherein said composition comprises from 1 to 10% by weight of said keratin.

### Claim 24 (depends on 19)

The composition of claim 19, wherein said keratin is from 3 to 5 percent by weight.

### Claim 25 (depends on 19)

The composition of claim 19, wherein said composition is formulated for parenteral administration.

### Claim 26 (depends on 19)

The composition of claim 19, wherein said anticoagulant comprises heparin.
